Zhejiang Hisun Pharmaceutical Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Kevin Xiao
Chief executive officer
CN¥869.5k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 1.1yrs |
| CEO ownership | n/a |
| Management average tenure | 5.5yrs |
| Board average tenure | no data |
Recent management updates
Recent updates
Zhejiang Hisun Pharmaceutical Co., Ltd.'s (SHSE:600267) Shares Lagging The Industry But So Is The Business
Sep 26
These 4 Measures Indicate That Zhejiang Hisun Pharmaceutical (SHSE:600267) Is Using Debt Reasonably Well
Apr 30Investors Don't See Light At End Of Zhejiang Hisun Pharmaceutical Co., Ltd.'s (SHSE:600267) Tunnel
Mar 29CEO
Kevin Xiao (55 yo)
1.1yrs
Tenure
CN¥869,500
Compensation
Mr. Weihong Xiao, also known as Kevin, has been Chief Executive Officer at Zhejiang Hisun Pharmaceutical Co., Ltd. since October 11, 2023. He served as Chief Operating Officer at 3SBio Inc. since March 201...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | 1.1yrs | CN¥869.50k | no data | |
| Senior Vice President | 5.5yrs | CN¥1.13m | 0.018% CN¥ 1.8m | |
| Senior Vice President | 5.5yrs | CN¥1.39m | 0.021% CN¥ 2.1m | |
| Director and Senior Vice President | 5.5yrs | CN¥2.13m | 0.021% CN¥ 2.1m | |
| Secretary of the Board | 7.1yrs | CN¥825.50k | 0.013% CN¥ 1.3m |
5.5yrs
Average Tenure
50yo
Average Age
Experienced Management: 600267's management team is seasoned and experienced (5.5 years average tenure).